Connor Clark & Lunn Investment Management Ltd. Acquires 14,706 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Connor Clark & Lunn raised its stake in Vertex by 7.1%, buying 14,706 shares to hold 220,801 shares worth about $86.5 million after the 3rd quarter.
• Phase 3 RAINIER results for povetacicept showed ~52% reduction in proteinuria for IgA nephropathy, triggering multiple analyst upgrades and higher price targets as Vertex pursues kidney‑disease expansion.
• Insider selling totaled 91,156 shares (~$42.85 million) over the last quarter, while institutional ownership remains high at about 90.96%.

Connor Clark & Lunn Investment Management Ltd. increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 220,801 shares of the pharmaceutical company's stock after acquiring an additional 14,706 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Vertex Pharmaceuticals worth $86,475,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in VRTX. Hohimer Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. Hohimer Wealth Management LLC now owns 2,123 shares of the pharmaceutical company's stock valued at $945,000 after purchasing an additional 26 shares during the last quarter. Legacy Wealth Asset Management LLC increased its position in shares of Vertex Pharmaceuticals by 1.8% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 1,442 shares of the pharmaceutical company's stock valued at $565,000 after purchasing an additional 26 shares during the last quarter. Quent Capital LLC increased its position in shares of Vertex Pharmaceuticals by 5.5% during the 3rd quarter. Quent Capital LLC now owns 501 shares of the pharmaceutical company's stock valued at $196,000 after purchasing an additional 26 shares during the last quarter. Washington Trust Advisors Inc. raised its holdings in Vertex Pharmaceuticals by 8.0% during the 3rd quarter. Washington Trust Advisors Inc. now owns 349 shares of the pharmaceutical company's stock valued at $137,000 after buying an additional 26 shares during the period. Finally, Defined Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 3.0% during the 3rd quarter. Defined Wealth Management LLC now owns 932 shares of the pharmaceutical company's stock valued at $365,000 after buying an additional 27 shares during the period. 90.96% of the stock is owned by institutional investors.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER data for povetacicept showed a large (~52%) reduction in proteinuria in IgA nephropathy, boosting hopes for an expedited regulatory filing and expansion of Vertex into kidney disease — a clear fundamental catalyst. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Positive Sentiment: Multiple banks raised price targets and reiterated Buy/Outperform ratings after the trial (Morgan Stanley, BofA, Oppenheimer, Citigroup, HC Wainwright, Truist, Jefferies, etc.), increasing analyst upside and supporting further gains. Analyst price target coverage roundup
• Positive Sentiment: Broker commentary and coverage upgrades (e.g., new coverage from Jefferies, maintained/raised ratings at BMO and others) reinforce investor confidence in povetacicept’s commercial potential and Vertex’s pipeline diversification. BMO Capital sticks to Buy rating
• Neutral Sentiment: Company presentations at healthcare conferences (Barclays, Leerink transcripts published) provide management commentary and additional detail for investors, but contain no new trial data beyond the RAINIER release. Barclays conference transcript
• Neutral Sentiment: Coverage in market media noted Vertex’s rising biotech weight in Nasdaq indices and broader attention following the trial — visibility that can attract flows but also raise short‑term trading interest. Biotech focus rises in Nasdaq index
• Negative Sentiment: After the big rally, the stock is pulling back (broader coverage flagged a larger intraday fall vs. the market); this looks like classic profit‑taking/mean reversion after rapid gains, increasing short‑term volatility risk. Vertex registers a bigger fall than the market
• Negative Sentiment: Zacks and other outlets also noted that recent earnings estimate revision trends and any lingering execution questions could temper momentum, so some analysts caution that the upside may be paced by upcoming filings and commercialization visibility. Will this strength last?

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 4,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total transaction of $2,137,455.00. Following the sale, the executive vice president owned 42,293 shares of the company's stock, valued at approximately $20,088,752.07. This trade represents a 9.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark E. Bunnage sold 2,021 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the completion of the transaction, the executive vice president owned 12,914 shares in the company, valued at $5,945,993.02. This represents a 13.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 91,156 shares of company stock valued at $42,845,497 over the last quarter. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $492.38 on Thursday. The stock has a market cap of $125.08 billion, a price-to-earnings ratio of 32.12 and a beta of 0.31. The firm's 50-day moving average is $469.19 and its two-hundred day moving average is $436.92. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. During the same quarter in the prior year, the firm posted $3.98 EPS. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on VRTX shares. HC Wainwright lifted their price objective on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a "buy" rating in a research note on Tuesday. Evercore increased their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an "outperform" rating in a research note on Friday, January 23rd. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $548.00 target price for the company in a report on Tuesday, January 6th. Oppenheimer lifted their price target on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a "hold" rating in a report on Friday, February 13th. Twenty-three research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $553.36.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.